← All trials
NCT04083911
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2019
- Primary completion
- May 31, 2021
- Completion date
- May 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Soochow UniversityLead sponsor
- Soochow UniversityOverall official - principal investigator
- Soochow UniversityCollaborator
- Changzhou No.2 People's HospitalCollaborator
- The First People's Hospital of LianyungangCollaborator
- Zhangjiagang First People's HospitalCollaborator
- Kunming Medical UniversityCollaborator
- The Second People's Hospital of Huai'anCollaborator
- Jingjiang People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.